Stock Analysis, Dividends, Split History

WVE / WAVE Life Sciences Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price46.70
Volume152,400.00
Market Cap ($M)1,156.94
Enterprise Value ($M)1,024.62
Book Value ($M)139.30
Book Value / Share4.75
Price / Book10.31
NCAV ($M)61.10
NCAV / Share2.08
Price / NCAV21.11
Share Statistics
Common Stock Shares Outstanding 27,829,079
Temporary Equity Shares Outstanding 3,901,348
Common Shares Outstanding 27,992,244
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.73
Return on Assets (ROA)-0.62
Return on Equity (ROE)-0.76
Balance Sheet (mrq) ($M)
Assets353.74
Liabilities206.57
Quick Ration/a
Current Ratio6.11
Income Statement (mra) ($M)
Revenues3,704,000.00
Operating Income-102.58
Net Income-102.03
Earnings Per Share Basic And Diluted-3.85
Cash Flow Statement (mra) ($M)
Cash From Operations-83.67
Cash from Investing-18.90
Cash from Financing-83.67
Identifiers and Descriptors
CUSIPY95308105
Central Index Key (CIK)1631574

Split History

Stock splits are used by WAVE Life Sciences Ltd. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

2018-08-09 zacks
Wave Life Sciences (WVE - Free Report) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.92 per share a year ago. These figures are adjusted for non-recurring items. (3-0)

Wave Life Sciences: What's Cooking Behind This Innovator?

2018-05-23 seekingalpha
Wave is innovating highly promising precision molecules that target various aspects of the “central dogma of biology” to potentially deliver hopes for patients worldwide. (45-0)

BRIEF-Wave Life Sciences Reports Qtrly Loss Per Share $1.26

2018-05-09 reuters
* WAVE LIFE SCIENCES LTD - ENDED Q1 OF 2018 WITH $110.5 MILLION IN CASH AND CASH EQUIVALENTS (7-0)

Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite

2018-05-09 seekingalpha
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. (69-3)

Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update

2018-05-08 seekingalpha
Synergy Pharma (NASDAQ:SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investors have taken up the cudgel against the management of Synergy. These investors have written to a number of wealthy individuals and funds to take a majority position in SGYP and bring about a change in leadership or sell the company outright. (446-2)

Silicon Investor Message Boards

This table lists all message boards related to WVE / WAVE Life Sciences Ltd. on message board site Silicon Investor.

WOLVERINE ENERGY (WVE.A) - Recommended in Buy Low, Sell Hi WOLVERINE ENERGY (WVE.A) - Recommended in Buy Low, Sell Hi WOLVERINE ENERGY (WVE.A) - Recommended in Buy Low, Sell Hi
CUSIP: Y95308105